Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin 2 mg/ml - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml excipient: glucose monohydrate hydrochloric acid lactic acid water for injection - uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 10 g - oral suspension - 100 mg/ml - active: ciprofloxacin 10 g excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin - oral suspension - 50 mg/ml - active: ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

Ísrael - enska - Ministry of Health

dexcel ltd, israel - ciprofloxacin as hydrochloride - caplets - ciprofloxacin as hydrochloride 500 mg - ciprofloxacin - ciprofloxacin - * adults :broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens. * children and adolescents:• broncho-pulmonary infections in cystic fibrosis caused by pseudomonas aeruginosa• complicated urinary tract infections and pyelonephritis• inhalation anthrax (post-exposure prophylaxis and curative treatment)ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no other alternative .treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents

Ísrael - enska - Ministry of Health

bioavenir ltd, israel - ciprofloxacin - solution for infusion - ciprofloxacin 200 mg / 100 ml - ciprofloxacin - ciprofloxacin - * adults :broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens.* children and adolescents:• broncho-pulmonary infections in cystic fibrosis caused by pseudomonas aeruginosa• complicated urinary tract infections and pyelonephritis• inhalation anthrax (post-exposure prophylaxis and curative treatment)ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no otheralternative .treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents

Írland - enska - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - ciprofloxacin - film-coated tablet - 250 milligram(s) - fluoroquinolones; ciprofloxacin

Írland - enska - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - ciprofloxacin - film-coated tablet - 500 milligram(s) - fluoroquinolones; ciprofloxacin

Írland - enska - HPRA (Health Products Regulatory Authority)

rowex ltd - ciprofloxacin - film-coated tablet - 250 milligram(s) - fluoroquinolones; ciprofloxacin

Írland - enska - HPRA (Health Products Regulatory Authority)

rowex ltd - ciprofloxacin - film-coated tablet - 500 milligram(s) - fluoroquinolones; ciprofloxacin

Írland - enska - HPRA (Health Products Regulatory Authority)

rowex ltd - ciprofloxacin - film-coated tablet - 750 milligram(s) - fluoroquinolones; ciprofloxacin